Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration

British Journal of Ophthalmology

Volumn 88, Issue 12, 2004, Pages 1557-1562

  Jonas, J B ^a,b   Kreissig, I ^b   Degenring, R F ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; EXUDATIVE RETINA MACULA AGE RELATED DEGENERATION; FEMALE; FOLLOW UP; GENDER; HUMAN; INTRAOCULAR HYPERTENSION; INTRAVITREAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REFRACTION ERROR; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT EPITHELIOPATHY; RETINA PIGMENT EPITHELIUM DETACHMENT; SNELLEN TEST TYPE; STEROID THERAPY; SUBFOVEA NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 9644254053     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.039552     Document Type: Article

References (47)

1. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001;132:425-7.
2. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
3. Jonas JB, Kreissig I, Söfker A, et al. Intravitreal in injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
4. Jonas JB, Hayler JK, Söfker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468-71.
5. Jonas JB, Hayler JK, Söfker A, et al. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001;10:284-7.
6. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247-8.
7. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graef Arch Clin Exp Ophthalmol 2002;240:782-3.
8. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-7.
9. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graef Arch Clin Exp Ophthalmol 2001;239:464-5.
10. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-72.
11. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380-3.
12. Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29:2-6.
13. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment of chronic uveitis. Br J Ophthalmol 2003;87:361.
14. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246-9.
15. Conway MD, Canakis C, Livir-Rallatos C, et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33.
16. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinalone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384-6.
17. Peyman GA, Cheema R, Conway MD, et al. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20:554-5.
18. Jonas JB. Concentration of intravitreally applicated triamcinolone acetonide in aqueous humour. Br J Ophthalmol 2002;86:1066.
19. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002;86:1450-1.
20. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6.
21. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:560-2.
22. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-2.
23. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
24. Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-3.
25. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-4.
26. Tano Y, Sugita G, Abrams G, et al. Inhibition of intraocular proliferation with intravitreal corticosteroid. Am J Ophthalmol 1980;89:131-6.
27. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of tramcinolone acetonide. Am J Ophthalmol 1980;90:810-16.
28. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neavascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-11.
29. Antoszyk AN, Gottlieb JL, Machemer R, et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neavascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
30. Penfold PL, Gyory JF, Hunyor AB, et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995;23:293-8.
31. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neavascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-104.
32. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-81.
33. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
34. Penfold PL, Wen L, Madigan MC, et al. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125-30.
35. Jonas JB, Kreissig I, Degenring RF. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graef Arch Clin Exp Ophthalmol 2002;240:873-4.
36. Penfold PL. Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol 2002;86:600-1.
37. Penfold PL, Wong JG, Gyory J, et al. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-92.
38. Ciulla TA, Criswell MH, Danis RP, et al. Intravitreol triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399-404.
39. Penn JS, Rajaratnam VS, Collier RJ, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283-90.
40. Ranson NT, Danis RP, Ciulla TA, et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-9.
41. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003;87:462-8.
42. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
43. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1177-87.
44. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;111:1329-45.
45. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
46. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-73.
47. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.